Preliminary results of a phase 2b trial (TANDEM, NCT03517540) showed that the combination of tropifexor with CVC was safe and able to reduce body weight and ALT in patients with biopsy-proven NASH with fibrosis. Here, GPT is linked to metabolic dysfunction-associated steatohepatitis.